MedTrace Logo

The CoAGulation Biomarkers and Atrial Fibrillation (COAG-AF) Pilot Study

NCT04947657 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-05

No results posted yet for this study

Summary

The aim of the Correlation Of CoAGulation-Atrial Fibrillation (COAG-AF) study is to prove that an increase in pro-thrombotic biomarkers in AF is associated with an increase in AF burden.

Secondary objectives of the study are the following:

* To investigate the impact of catheter ablation on serum pro-thrombotic biomarkers in patients with AF.
* To correlate coagulation biomarkers with imaging features such as, the degree of fibrosis found on Late Gadolinium Enhancement Magnetic Resonance Imaging (LGE-MRI) scans, which is a part of standard of care.
* To determine baseline values of coagulation and pro-thrombotic biomarkers in the AF population and compare those baseline values with the general population values.
* To compare central and peripheral thrombotic biomarkers in patients with atrial fibrillation.

Conditions

Sponsors & Collaborators

  • Tulane University

    lead OTHER

Principal Investigators

  • Amitabh Pandey, MD · Tulane University

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947657 on ClinicalTrials.gov